Analysis

6 Key Takeaways From High Court's Big Biosimilar Ruling

By Jeff Overley (June 12, 2017, 9:45 PM EDT) -- The U.S. Supreme Court delivered a smashing win for the youthful biosimilars industry by swatting away efforts to delay the lower-cost medicines, and its ruling teed up new battles for lower courts and maybe even Congress, attorneys say. Here are six key takeaways from Monday's ruling.

Early Notice Matches Law's Likely Intent

Monday's decision was nominally about a dispute between Amgen Inc. and Sandoz Inc., but it was mostly about setting rules for the whole biosimilars world. The decision's biggest headline was its conclusion that biosimilar makers need not wait for approval before supplying 180-day notice of sales under the Biologics...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!